Showing results (41-50 of 165) with videos related to
Sort By:
Pageof 17
The Journal of Urology|February 22, 2008
Extended pattern prostate biopsy does not minimize the volume-grade bias in prostate cancer detectionAbdullah M Al-Ghamdi, Gina Lockwood, Ants Toi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 20, 2008
External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomyShahrokh F Shariat, Jochen Walz, Claus G Roehrborn, et al.Scandinavian Journal of Urology|January 23, 2023
Low-volume grade group 2 prostate cancer candidates for active surveillance: a radical prostatectomy retrospective analysisJohan Björklund, Douglas C Cheung, Lisa J Martin, et al.European Urology Oncology|June 26, 2025
Radiation Therapy in the Management of Muscle-invasive Bladder Cancer with Carcinoma in Situ: Still a No Go?Constance Huck, Vérane Achard, Jason Efstathiou, et al.Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|December 10, 2013
Neoadjuvant chemotherapy should be administered to fit patients with newly diagnosed, potentially resectable muscle-invasive urothelial cancer of the bladder (MIBC): A 2013 CAGMO Consensus Statement and Call for a Streamlined Referral ProcessJo-An Seah, Normand Blais, Scott North, et al.European Urology|September 9, 2015
Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and OutcomesJakub Dobruch, Siamak Daneshmand, Margit Fisch, et al.European Urology|July 7, 2009
Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategyBas W G van Rhijn, Maximilian Burger, Yair Lotan, et al.The Prostate|May 13, 2015
Not all gleason pattern 4 prostate cancers are created equal: A study of latent prostatic carcinomas in a cystoprostatectomy and autopsy seriesFarshid Siadat, Jenna Sykes, Alexandre R Zlotta, et al.European Urology|June 21, 2011
Urine markers for detection and surveillance of non-muscle-invasive bladder cancerDerya Tilki, Maximilian Burger, Guido Dalbagni, et al.Urologic Oncology|July 27, 2020
Sequential administration of Bacillus Calmette-Guerin (BCG) and Electromotive Drug Administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade nonmuscle invasive bladder cancer after BCG failureTristan Juvet, Andrea Mari, Katherine Lajkosz, et al.Pageof 17